{
  "id": 8305252,
  "title": "Hims & Hers CFO Oluyemi Okupe sells $354,860 in stock",
  "url": "https://urgent.news/2026/09/18/hims-hers-cfo-oluyemi-okupe-sells-354-860-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T20:45:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/hims--hers-cfo-oluyemi-okupe-sells-354860-in-stock-93CH-4907880"
  },
  "original_language": "en",
  "account": "Hims & Hers Health CFO Oluyemi Okupe divested 12,313 shares of the company’s Class A Common Stock on September 17, 2026, selling them at $28.82 per share, generating a total of $354,860. This action occurred under a pre-existing Rule 10b5-1 trading plan initiated on May 20, 2026.\n\nPost-sale, Okupe now owns 251,804 shares directly, with an additional 7,853 shares indirectly held by the Oluyemi Okupe Separate Property Trust. Analysts suggest Hims & Hers Health is currently overvalued, with InvestingPro indicating this view. Investors can gain further insights through a Pro Research Report on Hims & Hers, available among 1,400+ US equities on the platform.\n\nHims & Hers Health reported its second-quarter 2026 earnings, leading Truist Securities to raise its stock price target to $32, maintaining a Hold rating. This upgrade was based on a review of proprietary card data and earnings disclosures. Conversely, Barclays adjusted its price target downward to $35, citing margin concerns despite anticipating faster revenue growth. Barclays now estimates Hims & Hers' fiscal 2026-2028 revenues to surpass earlier projections.\n\nMoreover, Hims & Hers expanded its offerings by launching branded GLP-1 weight-loss medications in Australia through its Pilot platform, following the acquisition of digital health platform Eucalyptus. However, the company faces challenges, including enrollment in Visa’s Acquirer Monitoring Program due to a rise in customer credit card disputes within its weight-loss subscription business. This has led to an $8 surcharge per dispute, totaling nearly $75,000.\n\nKeyBanc continues to maintain a Sector Weight rating on Hims & Hers, recognizing the company’s effective application of artificial intelligence with payback periods within 12 months.",
  "summary": null,
  "key_points": [
    "CFO Oluyemi Okupe sold $354,860 worth of Hims & Hers stock on September 17, 2026",
    "Okupe now owns 251,857 shares total, including 7,853 indirectly",
    "Analysts view Hims & Hers as potentially overvalued"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "NVIDIA CFO Colette Kress sells $7.6m in stock",
        "url": "https://urgent.news/2026/09/18/nvidia-cfo-colette-kress-sells-7-6m-in-stock",
        "published": "2026-09-18T22:01:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}